- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
CD142 antibody recognizes CD142, also known as Tissue Factor and Coagulation factor III (F3), a membrane-associated glycoprotein that functions as the primary initiator of the extrinsic coagulation cascade. CD142 antibody, also referred to as Tissue Factor antibody and F3 antibody in the literature, is widely used in studies of coagulation signaling, inflammatory activation, vascular injury response, and tumor-associated procoagulant pathways. CD142 is primarily localized at the plasma membrane where it binds coagulation factor VII and factor VIIa to initiate thrombin generation and downstream fibrin clot formation.
The F3 gene is located on chromosome 1p21.3 and encodes a transmembrane receptor belonging to the class II cytokine receptor family. The protein contains an extracellular ligand-binding region, a membrane-spanning domain, and a short cytoplasmic tail involved in intracellular signaling regulation. In addition to hemostatic functions, CD142 participates in inflammatory signaling, endothelial activation, angiogenesis, cellular migration, and tumor microenvironment remodeling. Through activation of PAR-dependent signaling pathways, Tissue Factor can influence MAPK and PI3K-AKT signaling networks associated with proliferation and survival responses.
The CD142 Antibody / Tissue Factor Coagulation Marker format is especially useful for investigations of coagulation biology, vascular signaling, inflammatory disease mechanisms, and tumor-associated thrombosis. CD142 expression is inducible in epithelial cells, endothelial cells, stromal cells, and activated monocytes during inflammatory stimulation or tissue injury. Cytokines such as TNF-alpha and IL1 beta can strongly upregulate CD142 expression, linking coagulation signaling with innate immune activation and endothelial dysfunction.
CD142 is also highly relevant in cancer biology because elevated Tissue Factor expression has been associated with lung cancer, pancreatic cancer, colorectal carcinoma, glioblastoma, ovarian cancer, and breast cancer. Increased CD142 activity contributes to tumor-associated thrombosis, angiogenic signaling, stromal remodeling, and metastatic progression. Because malignant tissue frequently develops procoagulant microenvironments, CD142 has become an important biomarker in studies examining aggressive tumor phenotypes and inflammatory tumor signaling.
Glycosylation of Tissue Factor can contribute to electrophoretic migration above the predicted unglycosylated molecular weight during western blot analysis. Membranous and cytoplasmic localization patterns are commonly observed in epithelial and tumor tissue, reflecting receptor trafficking and cell surface expression dynamics. Broad expression across normal and malignant tissue supports the role of CD142 as an interface between vascular injury signaling, inflammation, and cellular stress-response pathways.
Clone CD142/9196 is useful for investigating CD142 expression in vascular biology, coagulation signaling, inflammatory activation, and cancer-associated prothrombotic pathway research. This antibody supports studies examining epithelial tumor signaling, endothelial activation, and coagulation-associated cellular responses in normal and diseased tissue.
Additional studies involving coagulation signaling, inflammatory tumor microenvironments, and procoagulant pathway activation may benefit from our Tissue Factor antibody page featuring clone CD142/9195 for cancer and vascular biology research.
Optimal dilution of the CD142 Antibody / Tissue Factor Coagulation Marker should be determined by the researcher.
A portion of amino acids 50-250 from human Tissue Factor protein was used as the immunogen for the F3 / CD142 antibody.
Aliquot the F3 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
CD142 antibody, Tissue Factor antibody, F3 antibody, Coagulation factor III antibody, Thromboplastin antibody, Tissue thromboplastin antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.